nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—AOX1—Effects of Nitric Oxide—MB—peripheral nervous system neoplasm	0.0403	0.516	CbGpPWpGaD
Brimonidine—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.00175	0.0224	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (z) signalling events—GNAS—peripheral nervous system neoplasm	0.00111	0.0142	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (z) signalling events—GNAS—peripheral nervous system neoplasm	0.00104	0.0133	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (z) signalling events—GNAS—peripheral nervous system neoplasm	0.000843	0.0108	CbGpPWpGaD
Brimonidine—ADRA2C—Regulation of insulin secretion—SLC2A1—peripheral nervous system neoplasm	0.000839	0.0108	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000725	0.0093	CbGpPWpGaD
Brimonidine—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.00069	0.000748	CcSEcCtD
Brimonidine—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000688	0.000746	CcSEcCtD
Brimonidine—Abnormal vision—Doxorubicin—peripheral nervous system neoplasm	0.000688	0.000746	CcSEcCtD
Brimonidine—Eye pain—Epirubicin—peripheral nervous system neoplasm	0.000685	0.000743	CcSEcCtD
Brimonidine—Vision blurred—Cisplatin—peripheral nervous system neoplasm	0.000684	0.000742	CcSEcCtD
Brimonidine—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000684	0.000741	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000683	0.000741	CcSEcCtD
Brimonidine—ADRA2A—Regulation of insulin secretion—SLC2A1—peripheral nervous system neoplasm	0.000682	0.00874	CbGpPWpGaD
Brimonidine—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000681	0.000739	CcSEcCtD
Brimonidine—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000681	0.000739	CcSEcCtD
Brimonidine—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.000678	0.000736	CcSEcCtD
Brimonidine—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000676	0.000733	CcSEcCtD
Brimonidine—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000676	0.000733	CcSEcCtD
Brimonidine—ADRA2C—Regulation of insulin secretion—GNAS—peripheral nervous system neoplasm	0.000675	0.00866	CbGpPWpGaD
Brimonidine—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000675	0.000732	CcSEcCtD
Brimonidine—Oedema—Vincristine—peripheral nervous system neoplasm	0.00067	0.000726	CcSEcCtD
Brimonidine—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000667	0.000723	CcSEcCtD
Brimonidine—Infection—Vincristine—peripheral nervous system neoplasm	0.000665	0.000721	CcSEcCtD
Brimonidine—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000663	0.000719	CcSEcCtD
Brimonidine—ADRA2C—Integration of energy metabolism—SLC2A1—peripheral nervous system neoplasm	0.00066	0.00846	CbGpPWpGaD
Brimonidine—Diabetes mellitus—Doxorubicin—peripheral nervous system neoplasm	0.000658	0.000714	CcSEcCtD
Brimonidine—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000658	0.000714	CcSEcCtD
Brimonidine—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000658	0.000714	CcSEcCtD
Brimonidine—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000657	0.000712	CcSEcCtD
Brimonidine—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000654	0.000709	CcSEcCtD
Brimonidine—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000651	0.000706	CcSEcCtD
Brimonidine—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000649	0.000704	CcSEcCtD
Brimonidine—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000649	0.000704	CcSEcCtD
Brimonidine—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000649	0.000704	CcSEcCtD
Brimonidine—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000649	0.000704	CcSEcCtD
Brimonidine—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.000646	0.000701	CcSEcCtD
Brimonidine—Pain—Dactinomycin—peripheral nervous system neoplasm	0.000641	0.000695	CcSEcCtD
Brimonidine—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00064	0.000694	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—peripheral nervous system neoplasm	0.000634	0.000688	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000633	0.000687	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—peripheral nervous system neoplasm	0.000631	0.000685	CcSEcCtD
Brimonidine—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.000629	0.000682	CcSEcCtD
Brimonidine—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000626	0.000679	CcSEcCtD
Brimonidine—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.000624	0.000677	CcSEcCtD
Brimonidine—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00062	0.000672	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—peripheral nervous system neoplasm	0.000619	0.000671	CcSEcCtD
Brimonidine—Somnolence—Alitretinoin—peripheral nervous system neoplasm	0.000618	0.00067	CcSEcCtD
Brimonidine—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000618	0.00067	CcSEcCtD
Brimonidine—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.000615	0.000668	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000613	0.000665	CcSEcCtD
Brimonidine—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.000612	0.000663	CcSEcCtD
Brimonidine—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000611	0.000663	CcSEcCtD
Brimonidine—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.00061	0.000662	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00061	0.000662	CcSEcCtD
Brimonidine—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000606	0.000658	CcSEcCtD
Brimonidine—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000606	0.000658	CcSEcCtD
Brimonidine—Insomnia—Vincristine—peripheral nervous system neoplasm	0.000606	0.000657	CcSEcCtD
Brimonidine—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000601	0.000652	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.0006	0.000651	CcSEcCtD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000599	0.00768	CbGpPWpGaD
Brimonidine—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.000599	0.00065	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—peripheral nervous system neoplasm	0.000597	0.000648	CcSEcCtD
Brimonidine—Pain—Alitretinoin—peripheral nervous system neoplasm	0.000594	0.000644	CcSEcCtD
Brimonidine—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000592	0.000642	CcSEcCtD
Brimonidine—Infection—Cisplatin—peripheral nervous system neoplasm	0.000588	0.000638	CcSEcCtD
Brimonidine—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000584	0.000634	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.000584	0.000634	CcSEcCtD
Brimonidine—Rash—Topotecan—peripheral nervous system neoplasm	0.000583	0.000632	CcSEcCtD
Brimonidine—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000582	0.000632	CcSEcCtD
Brimonidine—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000581	0.00063	CcSEcCtD
Brimonidine—Cough—Etoposide—peripheral nervous system neoplasm	0.00058	0.000629	CcSEcCtD
Brimonidine—Headache—Topotecan—peripheral nervous system neoplasm	0.000579	0.000628	CcSEcCtD
Brimonidine—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000578	0.000627	CcSEcCtD
Brimonidine—Rash—Tretinoin—peripheral nervous system neoplasm	0.000578	0.000627	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000578	0.000627	CcSEcCtD
Brimonidine—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.000578	0.000627	CcSEcCtD
Brimonidine—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000578	0.000626	CcSEcCtD
Brimonidine—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000578	0.000626	CcSEcCtD
Brimonidine—Fatigue—Vincristine—peripheral nervous system neoplasm	0.000577	0.000626	CcSEcCtD
Brimonidine—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000575	0.000624	CcSEcCtD
Brimonidine—Headache—Tretinoin—peripheral nervous system neoplasm	0.000574	0.000623	CcSEcCtD
Brimonidine—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000574	0.000623	CcSEcCtD
Brimonidine—Hypertension—Etoposide—peripheral nervous system neoplasm	0.000574	0.000622	CcSEcCtD
Brimonidine—Pain—Vincristine—peripheral nervous system neoplasm	0.000573	0.000621	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—peripheral nervous system neoplasm	0.000572	0.000621	CcSEcCtD
Brimonidine—Rash—Melphalan—peripheral nervous system neoplasm	0.000571	0.000619	CcSEcCtD
Brimonidine—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00057	0.000618	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—peripheral nervous system neoplasm	0.000567	0.000615	CcSEcCtD
Brimonidine—Chest pain—Etoposide—peripheral nervous system neoplasm	0.000566	0.000614	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000562	0.000609	CcSEcCtD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.00056	0.00718	CbGpPWpGaD
Brimonidine—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000559	0.000606	CcSEcCtD
Brimonidine—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.000553	0.0006	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000553	0.0006	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—peripheral nervous system neoplasm	0.000553	0.000599	CcSEcCtD
Brimonidine—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000552	0.000599	CcSEcCtD
Brimonidine—Nausea—Topotecan—peripheral nervous system neoplasm	0.000549	0.000595	CcSEcCtD
Brimonidine—ADRA2A—Regulation of insulin secretion—GNAS—peripheral nervous system neoplasm	0.000548	0.00703	CbGpPWpGaD
Brimonidine—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000545	0.000591	CcSEcCtD
Brimonidine—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000545	0.000591	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000539	0.000585	CcSEcCtD
Brimonidine—Infection—Etoposide—peripheral nervous system neoplasm	0.000539	0.000584	CcSEcCtD
Brimonidine—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000538	0.000583	CcSEcCtD
Brimonidine—Nausea—Melphalan—peripheral nervous system neoplasm	0.000538	0.000583	CcSEcCtD
Brimonidine—ADRA2A—Integration of energy metabolism—SLC2A1—peripheral nervous system neoplasm	0.000536	0.00687	CbGpPWpGaD
Brimonidine—Influenza—Epirubicin—peripheral nervous system neoplasm	0.000535	0.00058	CcSEcCtD
Brimonidine—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000532	0.000577	CcSEcCtD
Brimonidine—ADRA2C—Integration of energy metabolism—GNAS—peripheral nervous system neoplasm	0.000531	0.00681	CbGpPWpGaD
Brimonidine—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.000529	0.000574	CcSEcCtD
Brimonidine—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000528	0.000573	CcSEcCtD
Brimonidine—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000527	0.000571	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—peripheral nervous system neoplasm	0.000525	0.000569	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—peripheral nervous system neoplasm	0.000514	0.000558	CcSEcCtD
Brimonidine—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000512	0.000555	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000512	0.000555	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000511	0.000554	CcSEcCtD
Brimonidine—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000507	0.00055	CcSEcCtD
Brimonidine—Pain—Cisplatin—peripheral nervous system neoplasm	0.000506	0.000549	CcSEcCtD
Brimonidine—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000499	0.000541	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000495	0.000537	CcSEcCtD
Brimonidine—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000493	0.000535	CcSEcCtD
Brimonidine—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000492	0.000533	CcSEcCtD
Brimonidine—AOX1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00049	0.00628	CbGpPWpGaD
Brimonidine—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000487	0.000528	CcSEcCtD
Brimonidine—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000484	0.000524	CcSEcCtD
Brimonidine—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000482	0.000523	CcSEcCtD
Brimonidine—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00048	0.000521	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000477	0.000517	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000476	0.000516	CcSEcCtD
Brimonidine—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000473	0.000513	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000468	0.000508	CcSEcCtD
Brimonidine—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000468	0.000507	CcSEcCtD
Brimonidine—Pain—Etoposide—peripheral nervous system neoplasm	0.000464	0.000503	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—peripheral nervous system neoplasm	0.000463	0.000503	CcSEcCtD
Brimonidine—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00046	0.000498	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000456	0.00585	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000455	0.00583	CbGpPWpGaD
Brimonidine—Sinusitis—Epirubicin—peripheral nervous system neoplasm	0.000447	0.000485	CcSEcCtD
Brimonidine—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000445	0.000483	CcSEcCtD
Brimonidine—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000443	0.00048	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	0.000441	0.000478	CcSEcCtD
Brimonidine—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000438	0.000475	CcSEcCtD
Brimonidine—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000438	0.000475	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000437	0.00561	CbGpPWpGaD
Brimonidine—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000436	0.000473	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000436	0.000473	CcSEcCtD
Brimonidine—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000435	0.000472	CcSEcCtD
Brimonidine—ADRA2A—Integration of energy metabolism—GNAS—peripheral nervous system neoplasm	0.000431	0.00553	CbGpPWpGaD
Brimonidine—Rhinitis—Epirubicin—peripheral nervous system neoplasm	0.000429	0.000465	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—peripheral nervous system neoplasm	0.000429	0.000465	CcSEcCtD
Brimonidine—ADRA2C—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000426	0.00547	CbGpPWpGaD
Brimonidine—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000425	0.000461	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000425	0.000461	CcSEcCtD
Brimonidine—AOX1—Disease—GNS—peripheral nervous system neoplasm	0.000423	0.00543	CbGpPWpGaD
Brimonidine—Rash—Vincristine—peripheral nervous system neoplasm	0.000422	0.000458	CcSEcCtD
Brimonidine—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000422	0.000457	CcSEcCtD
Brimonidine—Headache—Vincristine—peripheral nervous system neoplasm	0.000419	0.000455	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	0.000414	0.000449	CcSEcCtD
Brimonidine—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000413	0.000448	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—peripheral nervous system neoplasm	0.000412	0.000447	CcSEcCtD
Brimonidine—ADRA2C—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000409	0.00524	CbGpPWpGaD
Brimonidine—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000403	0.000437	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—peripheral nervous system neoplasm	0.0004	0.000434	CcSEcCtD
Brimonidine—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.0004	0.000433	CcSEcCtD
Brimonidine—Nausea—Vincristine—peripheral nervous system neoplasm	0.000398	0.000431	CcSEcCtD
Brimonidine—Flushing—Epirubicin—peripheral nervous system neoplasm	0.000397	0.000431	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000397	0.000431	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—peripheral nervous system neoplasm	0.000397	0.000431	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000393	0.000426	CcSEcCtD
Brimonidine—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000389	0.000422	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000388	0.000421	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000387	0.000419	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000386	0.000418	CcSEcCtD
Brimonidine—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000384	0.000416	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—peripheral nervous system neoplasm	0.000382	0.000415	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	0.000382	0.000414	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000375	0.000407	CcSEcCtD
Brimonidine—Rash—Cisplatin—peripheral nervous system neoplasm	0.000373	0.000405	CcSEcCtD
Brimonidine—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000373	0.000405	CcSEcCtD
Brimonidine—Erythema—Epirubicin—peripheral nervous system neoplasm	0.000373	0.000404	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	0.00037	0.000401	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000399	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000368	0.000399	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000365	0.000396	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000359	0.00039	CcSEcCtD
Brimonidine—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000359	0.000389	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.000388	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000357	0.000387	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000356	0.00456	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—GNS—peripheral nervous system neoplasm	0.000354	0.00454	CbGpPWpGaD
Brimonidine—Arrhythmia—Doxorubicin—peripheral nervous system neoplasm	0.000354	0.000384	CcSEcCtD
Brimonidine—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000352	0.000381	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—peripheral nervous system neoplasm	0.000351	0.000381	CcSEcCtD
Brimonidine—ADRA2B—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.000351	0.0045	CbGpPWpGaD
Brimonidine—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000347	0.000376	CcSEcCtD
Brimonidine—ADRA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000346	0.00444	CbGpPWpGaD
Brimonidine—Erythema—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000374	CcSEcCtD
Brimonidine—Rash—Etoposide—peripheral nervous system neoplasm	0.000342	0.000371	CcSEcCtD
Brimonidine—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000342	0.000371	CcSEcCtD
Brimonidine—Headache—Etoposide—peripheral nervous system neoplasm	0.00034	0.000369	CcSEcCtD
Brimonidine—AOX1—Metabolism—NME1—peripheral nervous system neoplasm	0.00034	0.00436	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000339	0.00434	CbGpPWpGaD
Brimonidine—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000338	0.000366	CcSEcCtD
Brimonidine—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000334	0.000362	CcSEcCtD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000332	0.00426	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000332	0.00426	CbGpPWpGaD
Brimonidine—Palpitations—Epirubicin—peripheral nervous system neoplasm	0.000329	0.000357	CcSEcCtD
Brimonidine—ADRA2C—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.000328	0.0042	CbGpPWpGaD
Brimonidine—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000327	0.000355	CcSEcCtD
Brimonidine—AOX1—Metabolism—COX2—peripheral nervous system neoplasm	0.000327	0.00419	CbGpPWpGaD
Brimonidine—Cough—Epirubicin—peripheral nervous system neoplasm	0.000325	0.000353	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—peripheral nervous system neoplasm	0.000325	0.000352	CcSEcCtD
Brimonidine—Nausea—Etoposide—peripheral nervous system neoplasm	0.000322	0.000349	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—peripheral nervous system neoplasm	0.000322	0.000349	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000344	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000344	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000317	0.000344	CcSEcCtD
Brimonidine—ADRA2C—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000316	0.00406	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000316	0.00406	CbGpPWpGaD
Brimonidine—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000316	0.000343	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000315	0.000342	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000313	0.00034	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.00031	0.000336	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.000335	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—peripheral nervous system neoplasm	0.000305	0.00033	CcSEcCtD
Brimonidine—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000304	0.00033	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.000329	CcSEcCtD
Brimonidine—Infection—Epirubicin—peripheral nervous system neoplasm	0.000302	0.000328	CcSEcCtD
Brimonidine—Cough—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.000326	CcSEcCtD
Brimonidine—Shock—Epirubicin—peripheral nervous system neoplasm	0.000299	0.000324	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000298	0.000323	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—peripheral nervous system neoplasm	0.000298	0.000323	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000297	0.000322	CcSEcCtD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000296	0.0038	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000296	0.0038	CbGpPWpGaD
Brimonidine—AOX1—Disease—PPP3R1—peripheral nervous system neoplasm	0.000296	0.00379	CbGpPWpGaD
Brimonidine—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000295	0.00032	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000318	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000318	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000293	0.000318	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000292	0.000317	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.000316	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00029	0.000314	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.000311	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—peripheral nervous system neoplasm	0.000284	0.000308	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000281	0.000305	CcSEcCtD
Brimonidine—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.000303	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000277	0.0003	CcSEcCtD
Brimonidine—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000277	0.0003	CcSEcCtD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000277	0.00355	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000277	0.00355	CbGpPWpGaD
Brimonidine—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000276	0.000299	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000275	0.000298	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.000298	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.000296	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.000273	0.000296	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000271	0.000294	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—peripheral nervous system neoplasm	0.00027	0.000293	CcSEcCtD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.00027	0.00346	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000269	0.00345	CbGpPWpGaD
Brimonidine—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.000268	0.00029	CcSEcCtD
Brimonidine—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.000266	0.00341	CbGpPWpGaD
Brimonidine—Hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.000285	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000263	0.000285	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000262	0.000284	CcSEcCtD
Brimonidine—Pain—Epirubicin—peripheral nervous system neoplasm	0.00026	0.000282	CcSEcCtD
Brimonidine—ADRA2B—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000258	0.00331	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000257	0.0033	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000257	0.00329	CbGpPWpGaD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000256	0.000278	CcSEcCtD
Brimonidine—AOX1—Disease—ENO2—peripheral nervous system neoplasm	0.000256	0.00329	CbGpPWpGaD
Brimonidine—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000254	0.000276	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000253	0.000274	CcSEcCtD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000251	0.00322	CbGpPWpGaD
Brimonidine—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000251	0.000272	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—peripheral nervous system neoplasm	0.00025	0.000271	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000248	0.000269	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000263	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000243	0.000263	CcSEcCtD
Brimonidine—ADRA2C—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000241	0.00309	CbGpPWpGaD
Brimonidine—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000261	CcSEcCtD
Brimonidine—ADRA2B—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000234	0.003	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000225	0.00288	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000225	0.00288	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000224	0.00288	CbGpPWpGaD
Brimonidine—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000224	0.000243	CcSEcCtD
Brimonidine—ADRA2C—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000219	0.0028	CbGpPWpGaD
Brimonidine—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000218	0.000237	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000233	CcSEcCtD
Brimonidine—AOX1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000215	0.00275	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000214	0.00274	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00021	0.00269	CbGpPWpGaD
Brimonidine—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000207	0.000225	CcSEcCtD
Brimonidine—AOX1—Disease—SLC2A1—peripheral nervous system neoplasm	0.000207	0.00265	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000205	0.00263	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000204	0.00262	CbGpPWpGaD
Brimonidine—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000202	0.000219	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000201	0.000218	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000216	CcSEcCtD
Brimonidine—ADRA2B—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000198	0.00254	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000196	0.00251	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000195	0.00251	CbGpPWpGaD
Brimonidine—Rash—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000208	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000192	0.000208	CcSEcCtD
Brimonidine—ADRA2C—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000191	0.00246	CbGpPWpGaD
Brimonidine—Headache—Epirubicin—peripheral nervous system neoplasm	0.00019	0.000207	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000186	0.000202	CcSEcCtD
Brimonidine—ADRA2C—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000185	0.00237	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000183	0.00235	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000183	0.00234	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000181	0.00233	CbGpPWpGaD
Brimonidine—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000181	0.000196	CcSEcCtD
Brimonidine—ADRA2B—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000179	0.0023	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000178	0.00228	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000177	0.00228	CbGpPWpGaD
Brimonidine—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000192	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.000192	CcSEcCtD
Brimonidine—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.000191	CcSEcCtD
Brimonidine—ADRA2A—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000174	0.00223	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000173	0.00222	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000171	0.0022	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—TH—peripheral nervous system neoplasm	0.000171	0.00219	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.00017	0.00218	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000167	0.00215	CbGpPWpGaD
Brimonidine—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000181	CcSEcCtD
Brimonidine—ADRA2C—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000166	0.00213	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000164	0.0021	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—GNAS—peripheral nervous system neoplasm	0.00016	0.00206	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000156	0.00199	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GNS—peripheral nervous system neoplasm	0.000155	0.00198	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000153	0.00196	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HGF—peripheral nervous system neoplasm	0.000153	0.00196	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.00015	0.00192	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—GNAS—peripheral nervous system neoplasm	0.00015	0.00192	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000148	0.0019	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—NME1—peripheral nervous system neoplasm	0.000148	0.0019	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HGF—peripheral nervous system neoplasm	0.000143	0.00183	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—COX2—peripheral nervous system neoplasm	0.000143	0.00183	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—GNAS—peripheral nervous system neoplasm	0.000139	0.00179	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KNG1—peripheral nervous system neoplasm	0.000139	0.00178	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000138	0.00177	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000137	0.00175	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	0.000136	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	0.000135	0.00173	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000133	0.0017	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000129	0.00166	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNS—peripheral nervous system neoplasm	0.000126	0.00161	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	0.000124	0.00159	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000124	0.00159	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	0.000122	0.00156	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	0.00012	0.00154	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	0.000116	0.00149	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000116	0.00149	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	0.000116	0.00149	CbGpPWpGaD
Brimonidine—AOX1—Disease—PTPN11—peripheral nervous system neoplasm	0.000116	0.00148	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000111	0.00143	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	0.000108	0.00139	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	0.000105	0.00135	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000105	0.00135	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000105	0.00134	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PTPN11—peripheral nervous system neoplasm	0.000104	0.00133	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	0.000101	0.0013	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000101	0.00129	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	9.83e-05	0.00126	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VIP—peripheral nervous system neoplasm	9.79e-05	0.00126	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.67e-05	0.00124	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	9.46e-05	0.00121	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ENO2—peripheral nervous system neoplasm	9.36e-05	0.0012	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	9.2e-05	0.00118	CbGpPWpGaD
Brimonidine—AOX1—Disease—ERBB2—peripheral nervous system neoplasm	9.13e-05	0.00117	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.04e-05	0.00116	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	8.79e-05	0.00113	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	8.59e-05	0.0011	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	8.45e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	8.39e-05	0.00108	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	7.98e-05	0.00102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.95e-05	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—BCHE—peripheral nervous system neoplasm	7.91e-05	0.00101	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	7.84e-05	0.00101	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	7.69e-05	0.000986	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	7.6e-05	0.000975	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.55e-05	0.000968	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TH—peripheral nervous system neoplasm	7.44e-05	0.000954	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.34e-05	0.000941	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	7.27e-05	0.000932	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	6.98e-05	0.000895	CbGpPWpGaD
Brimonidine—AOX1—Disease—NRAS—peripheral nervous system neoplasm	6.95e-05	0.000891	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.79e-05	0.00087	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—NRAS—peripheral nervous system neoplasm	6.7e-05	0.000859	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—peripheral nervous system neoplasm	6.47e-05	0.00083	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	6.42e-05	0.000824	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	6.39e-05	0.00082	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	6.37e-05	0.000817	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—NRAS—peripheral nervous system neoplasm	6.26e-05	0.000802	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KNG1—peripheral nervous system neoplasm	6.21e-05	0.000797	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	6.13e-05	0.000786	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GNAS—peripheral nervous system neoplasm	6.07e-05	0.000779	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	6.04e-05	0.000775	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	5.97e-05	0.000766	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ABCB1—peripheral nervous system neoplasm	5.96e-05	0.000764	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.92e-05	0.00076	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.81e-05	0.000744	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.53e-05	0.00071	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.51e-05	0.000707	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.43e-05	0.000697	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—peripheral nervous system neoplasm	5.12e-05	0.000657	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	5.08e-05	0.000652	CbGpPWpGaD
Brimonidine—AOX1—Disease—HRAS—peripheral nervous system neoplasm	5.08e-05	0.000652	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.08e-05	0.000651	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	4.93e-05	0.000632	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HRAS—peripheral nervous system neoplasm	4.9e-05	0.000628	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	4.85e-05	0.000622	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	4.84e-05	0.000621	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—peripheral nervous system neoplasm	4.79e-05	0.000614	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.72e-05	0.000605	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—peripheral nervous system neoplasm	4.58e-05	0.000587	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.49e-05	0.000576	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—peripheral nervous system neoplasm	4.49e-05	0.000575	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—peripheral nervous system neoplasm	4.33e-05	0.000555	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.12e-05	0.000529	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—peripheral nervous system neoplasm	4.04e-05	0.000518	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	3.89e-05	0.000499	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.84e-05	0.000493	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.78e-05	0.000484	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—peripheral nervous system neoplasm	3.76e-05	0.000482	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	3.72e-05	0.000477	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	3.59e-05	0.00046	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.53e-05	0.000452	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	3.28e-05	0.000421	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.98e-05	0.000383	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.92e-05	0.000374	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.87e-05	0.000367	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.81e-05	0.000361	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.79e-05	0.000358	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.73e-05	0.000351	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.71e-05	0.000347	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.63e-05	0.000337	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.55e-05	0.000328	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.53e-05	0.000325	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.48e-05	0.000318	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	2.32e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.27e-05	0.000291	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.26e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	2.13e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.12e-05	0.000272	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.12e-05	0.000271	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	2.07e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.06e-05	0.000264	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.98e-05	0.000253	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.88e-05	0.000242	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.74e-05	0.000223	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.72e-05	0.000221	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.66e-05	0.000213	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—peripheral nervous system neoplasm	1.64e-05	0.00021	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.62e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.6e-05	0.000206	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.55e-05	0.000199	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.47e-05	0.000188	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.37e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.32e-05	0.000169	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.26e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.11e-05	0.000143	CbGpPWpGaD
